Suchergebnisse - "Lebwohl, Mark"

1

Clobetasol Propionate Foam, 0.05%

von: Lebwohl, Mark

2001, in: American journal of clinical dermatology

Wird geladen...
2

Correction to: Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey

von: Lebwohl, Mark

2022, in: Dermatology and therapy

Wird geladen...
3

Do we need more psoriasis therapies?

von: Lebwohl, Mark

2015, in: Effects of shape functions on flexural–torsional buckling of fixed circular arches

Wird geladen...
4

33817 Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis who switched from secukinumab: Results from the open-label extension period of the BE RADIANT phase 3b trial

von: Lebwohl, Mark

2022, in: Plant uptake and translocation of contaminants of emerging concern in soil

Wird geladen...
5

43755 Rapid Reduction and Strict Complete Response in Itch With Oral Difelikefalin in Subjects With Notalgia Paresthetica and Moderate-to-Severe Pruritus

von: Lebwohl, Mark

2023, in: Journal of the American Academy of Dermatology

Wird geladen...
6

13065 More moderate levels of disease severity at baseline related to achievement of treatment targets with apremilast: Results from a pooled analysis

von: Lebwohl, Mark

2020, in: Plant uptake and translocation of contaminants of emerging concern in soil

Wird geladen...
7

Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey

von: Lebwohl, Mark

2021, in: Dermatology and therapy

Wird geladen...
8

16830 Results from the open-label treatment period of a long-term proactive management phase III trial using fixed-dose combination calcipotriene 0.005% and betamethasone dipropionate 0.064% foam

von: Lebwohl, Mark

2020, in: Journal of the American Academy of Dermatology

Wird geladen...
9

25031 Greater disease burden associated with palmoplantar pustulosis versus plaque psoriasis: Real-world evidence from the North American–based Corrona Psoriasis Registry

von: Lebwohl, Mark

2021, in: Plant uptake and translocation of contaminants of emerging concern in soil

Wird geladen...
10

Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)

von: Lebwohl, Mark

2021, in: Plant uptake and translocation of contaminants of emerging concern in soil

Wird geladen...
11

Two-Year US Pharmacovigilance Report on Brodalumab

von: Lebwohl, Mark

2020, in: Dermatology and therapy

Wird geladen...
12

Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions: Current and Future Trends

von: Lebwohl, Mark

2019, in: Drug safety

Wird geladen...
13

Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments

von: Lebwohl, Mark

2001, in: International journal of dermatology

Wird geladen...
14

34660 Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: Achievement of absolute PASI thresholds in the phase 3 POETYK PSO-1 and PSO-2 trials

von: Lebwohl, Mark

2022, in: Journal of the American Academy of Dermatology

Wird geladen...
15

18223 Long-term proactive management of psoriasis vulgaris with fixed-dose combination of 0.005% calcipotriene and 0.064% betamethasone dipropionate foam: Results of a phase III randomized controlled trial

von: Lebwohl, Mark

2020, in: Plant uptake and translocation of contaminants of emerging concern in soil

Wird geladen...
16

Reply to: “Comment on ‘Magnesium supplementation in the treatment of pseudoxanthoma elasticum: Is magnesium oxide the best choice?'”

von: Lebwohl, Mark

2019, in: Plant uptake and translocation of contaminants of emerging concern in soil

Wird geladen...
17

26842 Long-term proactive management with Cal/BD foam is beneficial for all patients with psoriasis irrespective of baseline characteristics

von: Lebwohl, Mark

2021, in: Plant uptake and translocation of contaminants of emerging concern in soil

Wird geladen...
18

27203 Psoriasis Area and Severity Index component scores in clinical trials of brodalumab

von: Lebwohl, Mark

2021, in: Plant uptake and translocation of contaminants of emerging concern in soil

Wird geladen...
19

43827 Deucravacitinib Long-term Efficacy in Patients Originally Randomized to Placebo: 2-Year Results From the POETYK PSO Program

von: Lebwohl, Mark

2023, in: Journal of the American Academy of Dermatology

Wird geladen...
20

Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry

von: Lebwohl, Mark

2024, in: Drugs - real world outcomes

Wird geladen...

1
2
3
4
5
6
7
8
9
10
11
Nächster
[11]

Nicht das Richtige dabei?

Schreiben Sie uns!